Milena Musilová
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)(2016)145 cited
- → Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML(2015)18 cited
- → Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study(2013)4 cited
- → BCR‐ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next‐generation sequencing(2014)3 cited
- → Extraktion von Ferroinperchlorat(1968)1 cited
- → Prospective analysis of low-levelBCR–ABL1T315I mutation in CD34 + cells of patients withde novochronic myeloid leukemia(2013)1 cited
- The prospective analysis of low-level BCR-ABL1 T315I mutation in the CD34(+) cells of de novo CML patients.(2013)
- → Pre-analytics optimization of non-invasive plasma specimens to improve KRAS mutation (KRASm) detection in patients with non-small cell lung cancer (NSCLC).(2015)
- DNMT3A gene: Distribution of the mutations and their stabilityduring treatment in patients with AML(2015)
- KRAS mutation detection details from various input plasma volumes.(2016)